Eton Pharmaceuticals shares rallied 25% in premarket trading on Friday after the company reported record quarterly revenue and issued 2026 guidance exceeding $145 million with an adjusted EBITDA margin target above 35%. CEO Sean Brynjelsen highlighted significant margin expansion and progress across the commercial portfolio and pipeline, along with several strategic transactions to support long-term growth. The company reiterated a net realized price of $8,000 to $10,000 for HEMANGEOL and said commercial focus is shifting to volume growth and converting patients from off-label adult product use. Eton Pharmaceuticals stock is up over 140% year to date.
Eton Pharmaceuticals IncRecord quarterly revenue and 2026 guidance above $145M with EBITDA margin above 35% drive positive outlook.
